IL309468A - Biomarkers for alzheimer's disease treatment - Google Patents

Biomarkers for alzheimer's disease treatment

Info

Publication number
IL309468A
IL309468A IL309468A IL30946823A IL309468A IL 309468 A IL309468 A IL 309468A IL 309468 A IL309468 A IL 309468A IL 30946823 A IL30946823 A IL 30946823A IL 309468 A IL309468 A IL 309468A
Authority
IL
Israel
Prior art keywords
biomarkers
alzheimer
disease
treatment
Prior art date
Application number
IL309468A
Other languages
English (en)
Hebrew (he)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL309468A publication Critical patent/IL309468A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL309468A 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment IL309468A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US202263364618P 2022-05-12 2022-05-12
PCT/US2022/073576 WO2023283650A1 (en) 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment

Publications (1)

Publication Number Publication Date
IL309468A true IL309468A (en) 2024-02-01

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309468A IL309468A (en) 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment

Country Status (11)

Country Link
US (1) US20250163135A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367516A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525559A (cg-RX-API-DMAC7.html)
KR (1) KR20240033017A (cg-RX-API-DMAC7.html)
AU (1) AU2022307687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225302A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000063A1 (cg-RX-API-DMAC7.html)
IL (1) IL309468A (cg-RX-API-DMAC7.html)
MX (1) MX2023015183A (cg-RX-API-DMAC7.html)
TW (1) TW202317192A (cg-RX-API-DMAC7.html)
WO (1) WO2023283650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076808A (zh) 2022-09-23 2025-05-30 卫材R&D管理有限公司 减少与神经退行性疾病相关的神经退行性变的方法
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
PT4121007T (pt) 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
CA3172451A1 (en) * 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Also Published As

Publication number Publication date
WO2023283650A1 (en) 2023-01-12
CL2024000063A1 (es) 2024-08-02
JP2024525559A (ja) 2024-07-12
CA3225302A1 (en) 2023-01-12
MX2023015183A (es) 2024-03-14
US20250163135A1 (en) 2025-05-22
EP4367516A1 (en) 2024-05-15
KR20240033017A (ko) 2024-03-12
TW202317192A (zh) 2023-05-01
AU2022307687A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
IL271046A (en) Compounds for treating huntington's disease
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
IL309208A (en) Neuroactive steroid for the treatment of alzheimer's disease
EP4153210A4 (en) MULTIPLE EPITOPE VACCINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL288940A (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
EP4061219A4 (en) ASSESSMENT SPEECH AUDIOMETRY
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
EP4021858A4 (en) TREATMENT OF AZOLES
EP3823616A4 (en) USE OF RILUZOLE PRODRUGS IN THE TREATMENT OF ALZHEIMER'S DISEASE
MA53636A (fr) Agent de traitement de troubles dermatologiques
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EP3628008A4 (en) COMPOSITION AND METHOD OF TREATMENT OF ALZHEIMER'S MORBUS
IL288793A (en) Compounds for treating respiratory disease
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
ZA202006126B (en) Compounds for treating alzheimer's disease
EP4010367A4 (en) Use of ass34 to assess alzheimer's disease progression
GB201915753D0 (en) Alzheimer's disease
EP3752614A4 (en) OLIGONUCLEOTIDE THERAPY FOR WILSON'S DISEASE